about
Tremelimumab: research and clinical developmentCutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaKinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.CTLA4 blockade broadens the peripheral T-cell receptor repertoireExposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaMetabolic control analysis in drug discovery and disease.Natural killer T cells in advanced melanoma patients treated with tremelimumabThe impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapyImproved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.PD-1 Blockade Expands Intratumoral Memory T Cells.Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanomaMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibodyDifferential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: a new strategy for antitumor drug development.Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping.Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.Focal Irradiation And Systemic Transforming Growth Factor β Blockade in Metastatic Breast Cancer.Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
P50
Q26752822-9F335E95-4638-4407-985B-74C20ADD2BB6Q27333987-40BB5699-B5AA-4D07-84DC-8316236517E0Q28749278-C5578A17-846C-4809-A4A0-00AA934E336AQ30496118-E69686BE-423E-4A24-9FB9-30EA6CB9F8C2Q33560753-994E8BD9-7DB8-4589-906D-E836F3673456Q33570005-91568DC0-3ED0-4476-B3EB-CAA177CD1226Q33806306-309F0CE3-2D23-41DE-AB75-E0CD92EA34B8Q34550535-87677FAF-FFD3-49AA-ADBA-121B8C0EC219Q35027661-889807A2-AF59-44FD-8987-7F7BBFE5EEEEQ35044159-610A2E73-1543-4CDF-92B1-251481745954Q36612452-7CED6D09-8C94-4252-A83E-8FB93CA82B0CQ36642804-8585C0D9-83F0-40AB-B486-C1D683517BF3Q36699335-B71B612B-749C-4102-88D1-0F69BF90EA34Q37222679-C0905B0D-8FDE-4D1D-BE66-2CD9DE824492Q37275680-31C881BE-5CC3-434C-B196-A9B7352C6215Q37394755-DC6B7EA3-F357-47E1-A8F4-86331DADF115Q39575747-AD89ACE8-620F-4628-A5A6-AD5F183D5FE0Q39712781-9265F3C5-D0DD-4994-B093-E7490E7C7E2DQ39803993-5916312D-3B29-4CD1-8012-C8BFB662B4EFQ40296204-46E34C58-140C-44C0-943E-6307893912B8Q40379585-DA004038-45AD-43BE-9C58-6B7BA87ECD1BQ41636546-0CB23A87-0DF3-46BD-A911-72D593AEADD9Q44144892-3BA39DC9-BBC7-4FF7-B263-8B055316D3BFQ46106546-F1019319-FB09-42C2-8859-F8FE4190C2CAQ46178232-DEBB59D4-8483-4BEA-87A9-C0F0E015D2FAQ46419929-B21A76CB-3A18-42DF-86A1-D42EABBEEBF8Q46555595-391E714F-558F-4261-88F8-3FE64C624FAAQ46843195-458DC4EE-08FD-469C-A779-5EBF7A1706ACQ50534906-6FAFA719-5406-4EC5-9E1B-2145230F33D5Q50535275-D519803F-2A75-4508-A9C8-DAE894FE5A97Q57171695-F2B27D46-F9E3-43F1-90B9-E00E9DDB90A7
P50
name
Begoña Comin-Anduix
@ast
Begoña Comin-Anduix
@en
Begoña Comin-Anduix
@nl
type
label
Begoña Comin-Anduix
@ast
Begoña Comin-Anduix
@en
Begoña Comin-Anduix
@nl
prefLabel
Begoña Comin-Anduix
@ast
Begoña Comin-Anduix
@en
Begoña Comin-Anduix
@nl